Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
The Bard PowerPort catheter lawsuit have been at the center of numerous claims regarding design and manufacturing defects.
This medical device, intended for the intravenous delivery of fluids and medications, has been reported to experience issues primarily due to the material properties of its Chronoflex catheter tubing, which is susceptible to fissuring and fracturing.
On this page, we’ll provide an overview of the Bard PowerPort Catheter Lawsuit, Bard PowerPort complications reported nationwide, studies on Bard PowerPort medical device defects, and much more.
The Bard PowerPort implanted device has been associated with these severe complications, leading to numerous legal actions against Bard Access Systems for prioritizing profits over patient safety.
As a result, there is ongoing multidistrict Bard PowerPort litigation focusing on these allegations, with claims still in the early investigation and litigation stages.
Common injuries noted in lawsuits related to the Bard PowerPort typically include:
These injuries not only pose immediate health risks but can also require additional medical interventions or surgeries, increasing the burden on patients.
If you or someone you love has experienced serious complications after receiving a Bard PowerPort catheter, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine your eligibility to join others filing in the Bard PowerPort MDL today.
The research documented in FDA adverse event reports and NIH-published studies has revealed significant concerns about the Bard PowerPort catheter device’s safety profile.
Multiple reports in the FDA’s MAUDE database and clinical studies have documented issues with device performance and patient outcomes.
Patients affected by the defective Bard PowerPort device may claim damages for severe injuries, including malfunction, migration, and life-threatening complications.
Clinical studies tracked through the FDA’s medical device reporting system have identified several areas of concern with the implantable port catheter device, specifically the PowerPort’s design and performance.
According to FDA documentation, the device underwent a Class 2 recall, indicating potential temporary or medically reversible health consequences.
Key findings from government sources include:
These research findings have been instrumental in establishing patterns of device failure and identifying potential safety concerns.
Government documentation through the MAUDE database has provided a systematic record of adverse events, while NIH studies have offered detailed analyses of complications and outcomes.
This body of evidence has become increasingly important as healthcare providers and patients seek to understand the risks associated with PowerPort devices.
The FDA’s MAUDE database and NIH research on implanted ports have documented numerous adverse events associated with PowerPort devices.
These reports detail complications ranging from minor issues to severe medical emergencies requiring immediate intervention.
Government sources such as the FDA MAUDE database confirm these primary complications:
The severity and frequency of these complications have led to significant concerns within the medical community.
According to NIH research, many of these complications require additional surgical interventions and extended hospital stays.
The documented pattern of device-related injuries has contributed to growing scrutiny of the PowerPort system’s safety profile and has become central to ongoing litigation efforts.
The research documented in NIH material analysis studies has revealed significant design and structural issues with the Bard implanted port catheter system.
Multiple scientific investigations have identified specific material vulnerabilities that may contribute to device failure and patient complications.
The Bard PowerPort, a port catheter device primarily used for chemotherapy treatments, has been the subject of ongoing lawsuits alleging design and manufacturing flaws, which can lead to severe complications for patients, including fractures, migration, and other serious injuries.
Laboratory studies of medical device materials have identified several critical concerns with the PowerPort’s design and composition.
The integration of barium sulfate with polyurethane materials has been particularly scrutinized for potential safety implications.
Material concerns documented in government studies include:
These material issues, documented through extensive NIH research, demonstrate significant concerns about the long-term stability of the device.
Laboratory analysis has shown that the combination of materials used in the PowerPort may create inherent weaknesses that develop over time, potentially compromising patient safety and device functionality.
Government studies on catheter complications have identified consistent patterns of device failure that raise serious concerns about Bard’s design integrity.
These patterns emerge from both laboratory testing and clinical observation.
Documented failure patterns include:
The frequency and consistency of these failure patterns, as documented in long-term performance studies, suggest fundamental issues with the device’s design and material composition.
Research indicates that these failures often develop gradually, making them particularly concerning for long-term implant patients who rely on the device for critical medical treatment.
Government research on implantable ports has documented numerous complications associated with Bard PowerPorts, including infections and blood clots.
Certain Bard PowerPort devices have been linked to serious injuries and defects, leading to ongoing multidistrict litigation and highlighting the importance of legal support for affected patients.
These adverse events range from immediate post-implantation issues to serious long-term medical complications that often require additional surgical intervention.
Clinical studies of port complications have identified distinct categories of device-related injuries that affect patient health and safety, including those associated with Bard Peripheral Vascular devices.
These complications often require immediate medical attention and can lead to serious health consequences.
Documented categories of injuries include:
According to extensive research on port-related complications, these injuries often develop in patterns that suggest systemic issues with the device’s design and functionality.
The frequency and severity of these complications have raised significant concerns about patient safety and the need for enhanced monitoring protocols.
Long-term studies of patient outcomes reveal significant ongoing health impacts for individuals affected by PowerPort complications.
These consequences often extend well beyond the initial device failure or complication.
Documented long-term consequences include:
The impact of these long-term health consequences, as documented in NIH research on port complications, demonstrates the significant burden placed on affected patients.
Studies indicate that many patients require ongoing medical care and face lasting impacts on their quality of life, often necessitating substantial changes to their healthcare management strategies.
Bard PowerPort catheter lawsuits are being filed by individuals across the country who were injured due to defective Bard PowerPort devices.
Consulting experienced Bard PowerPort lawyers is crucial for navigating the complexities of product liability claims and increasing the chances of securing compensation.
Potential plaintiffs can file a Bard PowerPort lawsuit by understanding the eligibility criteria and the legal support available to help secure financial compensation.
TruLaw is currently accepting clients for the Bard PowerPort catheter lawsuit.
A few reasons to choose TruLaw for your Bard PowerPort catheter lawsuit include:
If you or a loved one suffered injuries related to a defective Bard PowerPort catheter, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify for the Bard PowerPort catheter lawsuit today.
The Bard PowerPort catheter lawsuit involves allegations of design and manufacturing defects in devices used for intravenous delivery of fluids and medications.
The lawsuits claim that Bard failed to warn users about potential hazards and didn’t address design flaws in the Chronoflex catheter tubing that is prone to fissuring and fracturing.
The Bard PowerPort multidistrict litigation consolidates these claims, detailing processes like the completion of Plaintiff Fact Sheets, updates on the litigation’s progress, and ongoing court deliberations.
Common injuries associated with the PowerPort implantable port include catheter fractures, bloodstream infections, deep vein thrombosis, cardiac arrhythmias, and internal bleeding.
These complications often require additional medical interventions or surgeries and can lead to severe health consequences.
Multiple reports in the FDA’s MAUDE database and NIH-published studies have documented significant safety concerns and device failures.
The evidence includes clinical studies, adverse event reports, and a Bard PowerPort recall indicating potential temporary or medically reversible health consequences.
Laboratory studies have identified issues with the integration of barium sulfate with polyurethane materials and the structural degradation of components.
Research shows that the combination of materials creates inherent weaknesses that develop over time, compromising device functionality and patient safety.
Patients often experience chronic pain, recurring infections, permanent vascular damage, and ongoing medical monitoring requirements.
These long-term impacts significantly affect quality of life and typically require substantial changes to healthcare management strategies.
TruLaw operates on a contingency fee basis and offers expertise in handling medical device cases similar to the Bard PowerPort catheter lawsuit.
Affected individuals can receive an instant case evaluation through TruLaw’s chat feature to determine their eligibility for compensation.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?